Lundbeckfonden’s Jacob Falck Hansen becomes CEO of portfolio company Vesper Bio

Lundbeckfonden Biocapital’s Jacob Falck Hansen has stepped into the CEO role at portfolio company Vesper Bio ApS, a Copenhagen-based start-up advancing an oral SORT1 inhibitor to treat a genetically defined group of patients with frontotemporal dementia. Paul Little, who had been Vesper Bio’s CEO while serving as an operating partner with Lundbeckfonden, has parted ways with the firm as well, according to his LinkedIn profile.

Weeks after Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY) named Jared Kelly CEO, the Canadian oncology company has tapped Andrew Aromando to be its CBO. Both were at Ambrx Biopharma Inc. prior to its sale to Johnson & Johnson (NYSE:JNJ) last year; Aromando was Ambrx’s COO, while Kelly was its general counsel. The $2 billion acquisition of Ambrx by J&J capped a 15-month turnaround during which the biotech made its ADC for prostate cancer its top priority and rose from penny stock territory with a pair of data readouts...